

Nicola Farina

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1268864/publications.pdf>

Version: 2024-02-01

20
papers

1,361
citations

933447

10
h-index

940533

16
g-index

20
all docs

20
docs citations

20
times ranked

3569
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chester disease. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e11-e11. | 0.9 | 15 |
| 2 | The Role of the Multidisciplinary Health Care Team in the Management of Patients with Systemic Sclerosis. <i>Journal of Multidisciplinary Healthcare</i> , 2022, Volume 15, 815-824. | 2.7 | 6 |
| 3 | Patients' experience and tolerability with canakinumab and anakinra for the treatment of adult-onset Still's disease.. <i>Clinical and Experimental Rheumatology</i> , 2022, , . | 0.8 | 0 |
| 4 | Interleukin 6 inhibition in severe COVID-19: Another piece of the puzzle. <i>European Journal of Internal Medicine</i> , 2022, , . | 2.2 | 0 |
| 5 | Autoantibody positivity predicts severity of rheumatic immune-related adverse events to immune-checkpoint inhibitors. <i>European Journal of Internal Medicine</i> , 2022, 103, 95-99. | 2.2 | 6 |
| 6 | Drug retention rates of biological agents in adult onset Still's disease. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1-6. | 3.4 | 14 |
| 7 | Canakinumab injection for the treatment of active Stillâ€™s disease, including adult-onset Stillâ€™s disease. <i>Expert Opinion on Orphan Drugs</i> , 2021, 9, 77-86. | 0.8 | 1 |
| 8 | Catastrophic antiphospholipid syndrome presenting with aortic barrage: case report and review of the literature. <i>Lupus</i> , 2021, 30, 1005-1009. | 1.6 | 0 |
| 9 | Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study. <i>Lancet Rheumatology</i> , The, 2021, 3, e253-e261. | 3.9 | 140 |
| 10 | Beyond Neuropsychiatric Manifestations of Systemic Lupus Erythematosus: Focus on Post-traumatic Stress Disorder and Alexithymia. <i>Current Rheumatology Reports</i> , 2021, 23, 52. | 4.7 | 6 |
| 11 | Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series. <i>European Journal of Internal Medicine</i> , 2021, 93, 87-94. | 2.2 | 41 |
| 12 | Impact of the COVID-19 pandemic in patients with systemic lupus erythematosus throughout one year. <i>Clinical Immunology</i> , 2021, 231, 108845. | 3.2 | 14 |
| 13 | Current treatment options and safety considerations when treating adult-onset Stillâ€™s disease. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1549-1558. | 2.4 | 15 |
| 14 | COVID-19: Pharmacology and kinetics of viral clearance. <i>Pharmacological Research</i> , 2020, 161, 105114. | 7.1 | 17 |
| 15 | Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. <i>Lancet Rheumatology</i> , The, 2020, 2, e325-e331. | 3.9 | 808 |
| 16 | Low prevalence of arrhythmias in clinically stable COVIDâ€™19 patients. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2020, 43, 891-893. | 1.2 | 43 |
| 17 | GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study. <i>Lancet Rheumatology</i> , The, 2020, 2, e465-e473. | 3.9 | 173 |
| 18 | Obesity and its role in the management of rheumatoid and psoriatic arthritis. <i>Clinical Rheumatology</i> , 2020, 39, 1039-1047. | 2.2 | 32 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the Pandemic. <i>Frontiers in Pharmacology</i> , 2020, 11, 598308. | 3.5 | 29 |
| 20 | Patients' experience and tolerability with canakinumab and anakinra for the treatment of adult-onset Still's disease.. <i>Clinical and Experimental Rheumatology</i> , 0, , . | 0.8 | 1 |